NEW YORK (GenomeWeb News) — Fluidigm said today that it expects total revenue for the fourth quarter of 2013 to be approximately $21 million, beating consensus analyst estimates of $19.5 million and representing a 34 percent spike compared to Q4 2012 revenues of $15.7 million.

Based on preliminary, unaudited financial data, Fluidigm said that it expected Q4 instrument revenue to be approximately $12 million and consumables revenue to be approximately $8.5 million compared to $9.6 million and $5.8 million, respectively, in the same quarter last year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genomic analysis of Malaysian tuberculosis strain, database of bat genomes, and more.

An editorial appearing at The Scientist bemoans the high numbers of mitochondrial genome papers and suggests a different path for mitochondrial genome research.

Researchers and drug developers are excited about the potential of CRISPR-Cas9-based therapeutics, the Wall Street Journal reports.

US lawmakers want to develop a new incarnation of the National Children's Study, ScienceInsider reports.